ELCC 2026 highlights expanding roles for radiotherapy across modern thoracic oncology
ELCC 2026 highlighted growing integration of SBRT and thoracic radiotherapy with targeted therapy, immunotherapy and biomarker-guided treatment selection.
Tag
sbrt
Longer interval to surgery predicted response after preoperative SBRT for luminal breast cancer
Preoperative SBRT produced a pooled 21.4% pathological complete response rate, with irradiation-to-surgery interval strongly associated with response.
PTV coverage prescriptions poorly represented delivered tumor dose in lung SBRT
D95% and D98% PTV prescriptions produced substantial interpatient variability, while GTV- and ITV-based median or mean doses were more accurate.
SBRT plus dual checkpoint blockade produced 72.7% six-month PFS in oligometastatic HNSCC
Durvalumab, tremelimumab and SBRT produced 72.7% six-month progression-free survival in 33 patients with oligometastatic HNSCC.
Updated ASTRO guideline expands radiation therapy across pancreatic cancer settings
ASTRO expands radiation therapy recommendations across locally advanced, recurrent and oligometastatic pancreatic cancer, with new guidance on dose escalation and adaptation.
Time-series CT radiomics predicted rib fracture after lung SBRT with 0.79 validation AUC
A longitudinal CT radiomics model identified post-SBRT rib fracture risk with 85% sensitivity and 71% specificity in validation.
OCTAVIUS 4D achieved 98.3% gamma passing for MR-LINAC SBRT QA
Across 40 Unity SBRT plans, OCTAVIUS 4D achieved 98.3% mean local gamma passing with sub-degree angular agreement.
Rectal spacer geometry remained stable throughout five-fraction prostate SBRT
Hydrogel spacers showed no meaningful loss of geometry during prostate SBRT, supporting stable rectal separation across the treatment course.
Simulation-free adaptive lung SBRT was feasible in the ONE STOP pilot
Eight of ten patients completed simulation-free single-fraction adaptive lung SBRT, with treatment taking a median 72 minutes.
Deformable registration substantially changed cumulative dose estimates in stereotactic re-irradiation
DIR reduced estimated liver maximum dose from 123.8 to 83.2 Gy, but accuracy deteriorated markedly for bowel and stomach.
Empty-bladder prostate SBRT met the EMPTY-RT acute safety endpoint
Empty-bladder SBRT was feasible in 85% of screened patients, with grade 2 or higher urinary toxicity of 28.1%.
SBRT controlled bone lesions but rarely delayed systemic therapy in bladder cancer
Two-year local control reached 88%, but median progression-free survival was 5.8 months and systemic treatment changed after 4.4 months.
Omitted guideline-recommended sectors drove local failure after sacral SBRT
Seventy-three percent of failures after nonadherent sacral contouring involved sectors that guidelines recommended including in the clinical target volume.
Respiratory gating reduced lung SBRT target volumes and normal-tissue dose
A 30–70% gating window reduced planning target volume by 34% and mean lung dose by 0.75 Gy without compromising coverage.
Cardiac-dose model validated non-cancer death risk in one lung SBRT cohort
The model calibrated well only when non-cancer death was defined consistently; an overall-survival version validated in both external cohorts.